Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded NK Cells and Elotuzumab in High-Risk Myeloma
NCT03003728Phase 2Withdrawn
- Sponsor
- University of Arkansas
- Start
- Nov 2019
- Primary completion
- Jul 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of expanded natural killer cells in multiple myeloma (MM), sponsored by University of Arkansas. Planned start Nov 2019; status: withdrawn.
02
Drugs
expanded natural killer cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03003728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03003728.